ImmunoBrain Checkpoint
ImmunoBrain Checkpoint
Agent36Agent Readiness: 36/100. Below median. Measured by StartupHub.ai. Median 41.Biopharmaceutical company targeting neurodegeneration and aging by modulating the immune system.
About
ImmunoBrain Checkpoint is a biopharmaceutical company pioneering a transformative approach to treating neurological disorders by harnessing the power of the peripheral immune system to mitigate brain pathology. Their lead program, IBC-Ab002, is a novel anti-PD-L1 antibody currently being investigated in patients with early Alzheimer's disease. They aim to redefine the treatment of neurological disorders by targeting the peripheral immune system to benefit the brain.
Key facts
At-a-glance profile data
- Website
- immunobrain.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2016
- Employees
- 18
- Total funding
- -
- Business model
- B2B
Tech stack
Detected on immunobrain.com, last scanned 21 Sept 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
Add first review
Frequently asked
How many employees does ImmunoBrain Checkpoint have?
ImmunoBrain Checkpoint has approximately 18 people on record.